TRISENOX
Total Payments
$208,328
Transactions
7
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $208,328 | 7 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $202,054 | 2 | 97.0% |
| Consulting Fee | $6,000 | 2 | 2.9% |
| Travel and Lodging | $260.93 | 2 | 0.1% |
| Food and Beverage | $13.30 | 1 | 0.0% |
Payments by Type
Research
$202,054
2 transactions
General
$6,274
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination with Radiation Therapy for Patients with Malignant Gliomas | Teva Pharmaceuticals USA, Inc. | $103,998 | 0 |
| A Randomized, Open Label, Bioequivalence Study of XM02 Tbo-Filgrastim (Granix) and Filgrastim (Neupogen) when Administered in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma | Teva Pharmaceuticals USA, Inc. | $98,056 | 0 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $208,328
Product Information
- Type Drug
- Total Payments $208,328
- Total Doctors 2
- Transactions 7
About TRISENOX
TRISENOX is a drug associated with $208,328 in payments to 2 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $208,328 was paid across 7 transactions to 2 doctors.
The most common payment nature for TRISENOX is "Unspecified" ($202,054, 97.0% of total).
TRISENOX is associated with 2 research studies, including "A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination with Radiation Therapy for Patients with Malignant Gliomas" ($103,998).